Connor, Clark & Lunn Investment Management (CC&L)’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NBP Stock Details NBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-191,714	Closed	-$763K	–	1667
2025 Q4	$763K	Buy	191,714 +27,650	+17%	+$122K	﹤0.01%	1209
2025 Q3	$620K	Buy	164,064 +136,264	+490%	+$463K	﹤0.01%	1205
2025 Q2	$67.3K	Buy	+27,800	New	+$37.7K	﹤0.01%	1471
2023 Q4	–	Sell	-23,639	Closed	-$31.2K	–	1467
2023 Q3	$31.2K	Buy	+23,639	New	+$51.9K	﹤0.01%	1325
2023 Q1	–	Sell	-27,113	Closed	-$113K	–	1347
2022 Q4	$113K	Buy	+27,113	New	+$103K	﹤0.01%	1103

Other funds holding NBP

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ACM

AIHC Capital Management Central $120M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NBP Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of NovaBridge Biosciences American Depositary Shares (NBP) in Q1 2026, closing a stake of 191,714 shares — an estimated $763K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NBP in Q4 2022 and held it in 5 quarters. The position peaked at $763K in Q4 2025. 48 funds tracked by Wall St. Rank hold NBP as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining NovaBridge Biosciences American Depositary Shares position as of Q1 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 191,714 NovaBridge Biosciences American Depositary Shares shares in Q1 2026, an estimated $763K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NovaBridge Biosciences American Depositary Shares in Q4 2022 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s NovaBridge Biosciences American Depositary Shares position peaked at $763K in Q4 2025.
48 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.